Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ACT-128800 in Psoriasis

This study has been completed.
Information provided by:
Actelion Identifier:
First received: February 26, 2009
Last updated: November 11, 2009
Last verified: November 2009
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

Condition Intervention Phase
Plaque Psoriasis
Drug: ACT-128800
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis

Resource links provided by NLM:

Further study details as provided by Actelion:

Primary Outcome Measures:
  • Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit. [ Time Frame: Baseline to week 6 ]

Secondary Outcome Measures:
  • "Clear - almost clear" Physician Global Assessment (PGA) at Week 6 visit. [ Time Frame: Week 6 ]

Enrollment: 66
Study Start Date: October 2008
Study Completion Date: September 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: ACT-128800
ACT-128800 administered orally once daily
Placebo Comparator: B Drug: Placebo
Matching placebo capsules administered orally once daily


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified.

Exclusion Criteria:

  • Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.
  • Systemic or topical treatments for psoriasis other than emollients.
  • Ongoing bacterial, viral or fungal infections.
  • History or presence of malignancy.
  • Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852670

Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie
Graz, Austria, 8036
University Klinik of Vienna
Vienna, Austria, 1090
Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud
Lyon, France, 69000
CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie
Nice, France, 6202
Dermatologie, Hôpital Purpan Universtité Paul Sabatier
Toulouse, France, 31000
Klinik für Dermatologie Venerologie und Allergologie
Berlin, Germany, 10117
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Department of Dermatology University Hospital Johannes Gutenberg-University Mainz
Mainz, Germany, 55131
University Clinic Münster Clinic and Policlinic for skin diseases
Muenster, Germany, 48149
Semmelweis Universtity Dept. dermato-venerology and skin oncology
Budapest, Hungary, 1085
UNIVERSITY OF DEBRECEN Department of dermatology
Debrecen, Hungary, 4012
University of Szeged Department of dermatology and allergology
Szeged, Hungary, 6720
Veszprem County Csolnoky Ferenc Hospital Dermatology Department
Veszprem, Hungary, 8200
Clinical Centre of Nis Clinic of Dermato-venerology
Nis, Serbia, 18000
Sponsors and Collaborators
Study Director: Albrecht Georg Schmidt, MD Actelion
  More Information

Responsible Party: Sponsor, Actelion Identifier: NCT00852670     History of Changes
Other Study ID Numbers: AC-058A200
Study First Received: February 26, 2009
Last Updated: November 11, 2009

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on April 21, 2017